A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis

Thrombosis Research

Volumn 125, Issue 4, 2010, Pages

  Magnani, H N ^a  

^a NONE

Author keywords

Danaparoid sodium; Dosing recommendation; Heparin induced thrombocytopenia; Intermittent haemodialysis; Renal failure

Indexed keywords

CITRIC ACID; DANAPAROID; HEPARIN; WARFARIN;

ARTICLE; BLEEDING; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTINUOUS INFUSION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMODIALYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LOADING DRUG DOSE; MORTALITY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCORING SYSTEM; SKIN NECROSIS; THROMBOCYTE COUNT; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

CHONDROITIN SULFATES; DERMATAN SULFATE; FEMALE; HEMORRHAGE; HEPARIN; HEPARITIN SULFATE; HUMANS; PLATELET COUNT; PREGNANCY; RECURRENCE; RENAL DIALYSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 77949655733     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.10.008     Document Type: Article

References (74)

1. Meuleman D.G. Orgaran (Org10172): Its pharmacological profile in experimental models. Haemost 22 (1992) 58-65
2. Ofosu F.A. Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849). Haemost 22 (1992) 66-72
3. Danhof M., de Boer A., Magnani H.N., and Stiekema J.C.J. Pharmacokinetics considerations on Orgaran (Org 10172) therapy. Haemost 22 (1992) 73-84
4. Adachi M., Nakatsuka M., Sasaki A., Noguchi S., Kamata Y., Lin H., Shimizu K., and Hiramatsu Y. Effect of danaparoid on antiphospholipid positive infertile patients (2006) English translation of an unspecified Japanese publication 2006
5. ten Cate H., Henny Ch.P., ten Cate J.W., Büller H.R., Mooy M.C., Surachno S., and Wilmink J.M. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb Res 38 (1985) 211-222
6. Bradbrook I., Magnani H.N., Moelker H.C., Morrison P., Robinson J., Rogers H.J., Spector R.G., van Dinther T., and Wijnand H. Org 10172 a low molecular weight heparinoid anticoagulant with a long half-life in man. B J Clin Pharmacol 23/6 (1987) 667-675
7. Mikhailidis D.P., and Jagroop I.A. Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans. (Letter). J Int Med 244/2 (1998) 184
8. van Barlingen H.H., van Beek A., Erkelens D.W., and de Bruin T.W. Danaparoid: an antithrombotic agent without major impact on triglyceride hydrolysis capacity in humans. J Int Med 242/2 (1997) 125-129
9. Chong B.H., Ismail F., Cade J., Gallus A.S., Gordon S., and Chesterman C.N. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid. Org 10172. Blood 73 (1989) 1592-1596
10. Krauel K., Furil B., Warkentin T.E., Weitschies W., Kohlmann T., Sheppard J.A., and Greinacher A. Heparin-induced thrombocytopenia - therapeutic concentrations of danaparoid unlike fondaparinux and direct thrombin inhibitors, inhibit formation of PF4/heparin complexes. J Thromb Haemost 6 (2008) 2160-2167
11. Warkentin T.E., Greinacher A., Koster A., and Lincoff A.M. Treatment and Prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence based clinical practice guidelines (8th Edition). Chest 133 (2008) 340-380
12. Schmal K.S., Ganjoo A.K., and Harloff M.G. Orgaran® (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: role of adjunctive plasmapheresis. J Cardiothorac Vasc Anesth 11 (1997) 262-263
13. D Börker personal communication 1998.
14. Nurmohamed M.T., Fareed J., Hoppensteadt D., Walenga J.M., and ten Cate J.-W. Pharmacological and clinical strudies with Lomoparan, a low molecular weight glycosaminoglycan. Sem Thromb Hemost 17 Suppl 2 (1991) 205-213
15. Tholl U., Greinacher A., Overdick K., and Anlauf M. Life-threatening anaphylactic reaction following parathyroidectomy in a dialysis patient with heparin-induced thrombocytopenia. Nephrol Dial Transplant 12 (1997) 2750-2755
16. Neuhaus T.J., Goetschel P., Schmugge M., and Leumann E. Heparin-induced thrombocytopenia Type II in haemodialysis: switch to danaparoid. Pediatr Nephrol 14 8-9 (2000) 713-716
17. Haviv Y.S. Anaphylactic reaction to heparin sulphate in a haemodialysis patient. Clin Nephrol 54/6 (2000) E2-E3
18. Davenport A. Pyrexia of unknown origin in a haemodialysis patient. Nephrol Dial Transplant 2 (2008) 109-111
19. Magnani H.N., and Gallus A. Heparin induced thrombocytopenia: A report of 1478 clinical outcomes of patients treated with danaparoid (Orgaran®) from 1982 to mid 2004. Thromb Haemost 95/6 (2006) 967-981
20. Ireland H., Lane D.A., Flynn A., Anastassiades E., and Curtis J.R. The anticoagulant effect of Org10172 during haemodialysis: an objective assessment. Thromb Haemost 55 2 (1986) 271-275
21. von Bonsdorff M., Stiekema J., Harjanne A., and Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int J Artif Organs 13 2 (1990) 103-108
22. Henny Ch.P., ten Cate H., and Surachno S. P Stevens, Buller HR, Hartog M den, Cate JW ten. The effectiveness of low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 54 2 (1985) 460-462
23. Frei U., Wilkes M.F., Boehmer S., Crisp-Lindgren M., Schwarzrock R., Stiekema J.C.J., and Koch K.M. Gastro-intestinal blood loss in haemodialysis patients during the use of a low molecular weight heparinoid antocoagulant. Nephrol Dial Transplant 3 (1988) 435-439
24. Polkinghorne K.R., McMahon L.P., and Becker G.J. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane) and danaparoid sodium (Orgaran) in stable chronic haemodialysis patients. Am J Kidney Dis 40 5 (2002) 990-995
25. Hutchinson C.A., and Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant 22 (2007) 1680-1684
26. Bouman C.S.C., Royakkers A.A.N.M., Smits M., and Schulz M.J. Discrepancies between present guidelines and clinical practice in renal replacement therapy in critically ill patients with acute kidney injury: a Dutch survey. Neth J Crit Care 12 6 (2008) 260-268
27. Magnani H.N., and Wester J.P.J. Orgaran® use in ICU patients with heparin-induced thrombocytopenia and acute renal failure. J Clin Care (2007) Abstr A 717
28. Tardy-Poncet B.
29. Williamson D.R., Boulanger I., Tardif M., Albert M., and Gregoire G. Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacother 24 3 (2004) 409-414
30. Kodityal S., Manhas A.H., Udden M., and Rice L. Danaparoid for heparin-induced thrombocytopenia: an anlysis of treatment failures. Eur J Haematol (2003) 109-110
31. Lo G.K., Juhl D., Warkentin T.E., Sigouin C.S., Eichler P., and Greinacher A. Evaluation of pre-test clinical score (4 Ts) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4 (2006) 759-765
32. Chong B.H., Burgess J., and Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 69 (1993) 344-350
33. Greinacher A., Michels I., Kiefel V., and Mueller-Eckhardt C. A rapid and sensitive test for diagnosing heparin-induced thrombocytopenia. Thromb Haemost 66 6 (1991) 734-736
34. Sheridan D., Carter C., and Kelton J.G. A diagnostic test for heparin-induced thrombocytopenia. Blood 67 1 (1986) 27-30
35. Acostamadiedo J.M. Danaparoid sodium. Exp Opin Pharmacother 1 4 (2000) 803-814
36. Heparin-induced Thrombocytopenia Ed Warkentin TE, Greinacher A, Publ. Informa healthcare 200;Appendix 5:Page 537.
37. Henny Ch.P., ten Cate H., ten Cate J.W., Surachno S., van Bronswijk H., Wilmink J.M., and Ockleford P.A. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet i (1983) 890-893
38. Ben Ami R., Rachmimov S., and Berliner S. Danaparoid sodium for dialysis in heparin-induced thrombocytopenia. Harefuah 136 5 (1999) 361-364
39. Betz C., Kraus D., Muller C., and Geiger H. Iliac cuffed tunneled catheters for haemodialysis vascular access. Nephrol Dial Transplant 21 (2006) 2009-2012
40. Bredlich R.O., Stracke S., Gall H., and Proebstle T.M. Heparinassoziertes ThromboZyten-Aggregationssyndrom mit Hautnekrosen bei Hämodialyse. Dtsch med Wschr 122 11 (1997) 328-332
41. Charif R., and Davenport A. Heparin-induced thrombocytopenia: an uncommon but serious complication of heparin use in renal replacement therapy. Haemodialysis Int 10 (2006) 235-240
42. Finlay S., Price N.J., Crowther M., and Bloomfield R. Acute HIT should be considered when cardiac arrest follows line insertion and/or heparin administration. Scottish Med J 52/2 (2007) Abstract oral presentation
43. Faratro R., D'Gama C., and Chan C. The use of alternative anticoagulation strategies for a nocturnal home dialysis patient with heparin-induced thrombocytopenia. CANNT J 18/4 (2008) 32-35
44. Greinacher A., Philippen K.H., Kemkes-Mathes B., and Mockl M. Mueller-Eckhardt, Schaefer K. Heparin-associated thrombocytopenia Type II in a patient with end-stage renal disease: successful anticoagulation with the low molecular weight heparinoid Org 10172 during haemodialysis. Nephrol Dial Transplant 8 (1993) 1176-1177
45. Greinacher A. How to manage heparin-induced thrombocytopenia: update. 2007 Marketing brochure Organon Int.
46. Hill G.R., Hickton C., Henderson S., and Patton W.N. The use of low dose Orgaran® in heparin-induced thrombocytopenia associated with in-vitro platelet aggregation at higher Orgaran concentrations. Clin Lab Haem 19 (1997) 155-157
47. Ishida K., Imamaki M., Ishida A., Shimura H., and Miyazaki M. Heparin-induced thrombocytopenia after coronary artery bypass grafting with cardiopulmonary bypass: report of a case. Surg Today 34 (2004) 1041-1043
48. John G., Shehabi Y., and Mudaliar Y. Use of a low molecular weight preparation of heparin - Org 10172 (Lomoparan) in the critically ill. Anaesth. Intensive Care 19 4 (1991) 588-591
49. Kuhn B. Heparin-induzierte Thrombozytopenie - eine ernstzunehmende Komplikation im Rahmen einer Heparin Therapie. Unfallchirurg 100 (1997) 646-650
50. Lamriben L., Tiberghien F., Delacour J.L., et al. Intérêt de l'Orgaran en hémodialyse au cours d'une thrombopénie a l'héparine. La Presse Médicale 25 28 (1996) 1303
51. Lischetski G., Dittrich K., Topf H.-G., and Klinge J. Pediatric heparin-induced thrombocytopenia type II on dialysis. Haemostaseologie 24 (2004) A48 abstract P38
52. Mahul Ph., Raynaud J., Favre J.P., et al. Thrombopénie a l'héparine sous hémodialyse en réanimation: utilisation d'un héparinoïde de bas poids moleculaire, l'Org 10172 (Orgaran®). Ann Fr Anesth Reanim 14 (1995) 29-32
53. Montagnac R., Schillinger F., and Brahimi S. Use of danaparoid sodium (Org 10172; Orgaran) in haemodialysis in other indications that heparin induced thrombocytopenia. J Am Soc Nephrol 14 (2003) 816A-819A
54. Moonen M., and Rorive G. Low molecular weight heparinoid Org 10172 (Orgaran®) during continuous veno-venous haemofiltration in patients with heparin-induced thrombocytopenia. Nephrol Dial Transplant 12 (1997) A169
55. Roe S.D., Cassidy M.J.D., Haynes A.P., and Byrne J.L. Heparin-induced thrombocytopenia (HIT) and thrombosis in a haemodialysis-dependent patient with systemic vasculitis. Nephrol Dial Transplant 14 12 (1998) 3226-3229
56. von Roth B., Herkenrath P., Krebber J., and Anschutz K. Use of a new heparinoid as the sole anticoagulant in haemodialysis of paediatric patients. Nieren- und Hochdrukkrankheiten 14/21 (1985) 164
57. Rowlings P.A., Mansberg R., Rozenberg M.C., Evans S., and Murray B. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis. Aust NZ J Med 21 (1991) 52-54
58. Smoot E.C., Marx A., Weiman D., and Deitcher S.R. Recognition, diagnosis and management of heparin-induced thrombocytopenia and thrombosis. Plast Reconstr Surg 103 2 (1999) 559-565
59. Sturtevant J.M., Pillans P.I., Mackenzie F., and Gibbs H.H. Heparin-induced thrombocytopenia: recent experience in a large teaching hospital. Int Med J 36 (2006) 431-436
60. Tardy-Poncet B., Reynaud J., Tardy B., Mahul P., Mismetti P., and Guyotat D. Efficacy and safety of Orgaran® anticoagulation in patients with heparin-induced thrombocytopenia. Thromb Haemost 73 (1995) 1323 Abstract No. 1627
61. Verdy E., Debrix I., Benomar A., Becker A., and Flahault A. Impact d'une organization pluridisciplinaire pour la 'juste prescription' du danaparoide sodique en cas de suspicion de thrombopenie immune-allergique a l'heparine. Crit Care 10/6 (2006) R161
62. Zimmermann-Schroeder J., Castedello Th., and Bahmer F.A. Heparin-induzierte Nekrosen, bei dialysepflichtiger Niereninsuffizienz. Zeitschr Hautkrankheiten H+G5 73 (1998) 273-278
63. Baker J., DeLoughery T.G., and Boshkov L. Lack of value of clinical prediction of heparin-induced thrombocytopenia (HIT) in complex patients. Blood 104/11 (2004) Abstr 2065
64. Schenk J.F., Pindur G., Stephan B., Mörsdorf S., Mertzlufft F., Kroll H., Wenzl E., and Ulrich T.S. On the prophylactic and therapeutic use of danaparoid sodium (Orgaran®) in patients with heparin-induced thrombocytopenia. Clin Appl Thromb/Haemost 9/1 (2003) 25-32
65. Farner B., Eichler P., Kroll H., and Greinacher A. A comparison of lepirudin and danaparoid in patients with heparin-induced thrombocytopenia (HIT). Thromb Haemost 85 (2001) 950-957
66. Chong B.H., Gallus A.S., Cade J.F., Magnani H., Manoharan A., Oldmeadow M., Arthur C., Rickard K., Gallo J., Lloyd J., Seshadri P., and Chesterman C.N. Prospective open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 86 (2001) 1170-1175
67. Lubenow N., Warkentin T.E., Greinacher A., Wessel A., Sloane D.-A., Krahn E.L., and Magnani H.N. Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Haemost 117 (2006) 507-515
68. Strauss R., Wehler M., Mehler K., Kreutzer D., Eckard C., and Hahn G. Thrombocytopenia in patients in medical intensive care setting: bleeding prevalence, transfusion requirements and outcome of treatment. Intens Care Med 30 (2002) 1765-1771
69. Gettings E.M., Brush K.A., Van Cott E.M., and Hurford W.E. Outcome of post-operative critically ill patients with heparin-induced thrombocytopenia (an observational retrospective case control study). Crit Care 16/10 (2006) Electronic publication
70. Kress D.C., Aronson S., McDonald M.L., Malik M.I., Divgi A.B., Tector A.J., Downey F.X., Anderson A.J., Stone M., and Clancy C. Positive Heparin-Platelet Factor 4 antibody complex and cardiac surgical outcomes. Ann Thorac Surg 83 (2007) 1737-1743
71. Schenk S., El-Banayosy A., Morshuis M., Arusoglu L., Eichler P., Lubenow N., Tenderich G., Koerfer R., Greinacher A., and Prohaska W. IgG classification of anti-PF4/heparin antibodies to identify patients with heparin-induced thrombocytopenia during mechanical circulatory support. J Thromb Haemost 5/2 (2007) 235-241
72. Newman P.M., Swanson R.L., and Chong B.H. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80 (1998) 292-297
73. Warkentin T.E. Danaparoid sodium (Orgaran®) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in-vitro thrombin and cross-linked fibrin generation and evaluation if the clinical significance of in-vitro cross reactivity (XR) of danaparoid for HIT IgG. Blood 88 1 (1996) 626A Abstr 2493
74. Hoffman U., Huhle G., Haseroth K., Heene D.L., and Harenberg J. A fatal complication in a patient with heparin-induced thrombocytopenia type II re-exposed to heparin. Eur J Surg Traumatol 9 (1999) 205-207